[RHBBANK] QoQ Quarter Result on 31-Mar-2023 [#1]

Stock
[RHBBANK] RHB BANK BERHAD
Announcement Date
26-May-2023
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2023
Quarter
31-Mar-2023 [#1]
Profit Trend
QoQ- -1.35%
YoY- 26.89%
Quarter Report
Latest QR
Upcoming QR
RHBBANK's Result
RHBBANK's Financial Summary
View:
Show?
Quarter Result
31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 CAGR
Revenue 4,399,120 4,215,739 4,047,701 3,917,971 3,950,197 3,484,812 2,985,919 29.38%
PBT 805,754 879,318 1,063,090 1,005,182 1,222,142 1,039,290 1,018,802 -14.44%
Tax -218,469 -228,432 -253,391 -242,553 -448,201 -338,045 -383,219 -31.17%
NP 587,285 650,886 809,699 762,629 773,941 701,245 635,583 -5.11%
-
NP to SH 585,911 649,949 808,700 761,668 772,115 700,478 634,828 -5.19%
-
Tax Rate 27.11% 25.98% 23.84% 24.13% 36.67% 32.53% 37.61% -
Total Cost 3,811,835 3,564,853 3,238,002 3,155,342 3,176,256 2,783,567 2,350,336 37.91%
-
Net Worth 30,874,565 29,910,137 29,907,515 29,884,096 28,619,247 28,044,431 27,051,673 9.18%
Dividend
31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 CAGR
Div 1,071,587 - 640,125 - 1,058,294 - 623,147 43.39%
Div Payout % 182.89% - 79.15% - 137.06% - 98.16% -
Equity
31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 CAGR
Net Worth 30,874,565 29,910,137 29,907,515 29,884,096 28,619,247 28,044,431 27,051,673 9.18%
NOSH 4,286,348 4,286,348 4,286,348 4,247,373 4,247,373 4,212,077 4,212,077 1.16%
Ratio Analysis
31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 CAGR
NP Margin 13.35% 15.44% 20.00% 19.46% 19.59% 20.12% 21.29% -
ROE 1.90% 2.17% 2.70% 2.55% 2.70% 2.50% 2.35% -
Per Share
31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 CAGR
RPS 102.63 98.35 94.85 92.24 93.32 82.73 71.88 26.71%
EPS 13.67 15.16 18.95 17.93 18.24 16.63 15.28 -7.13%
DPS 25.00 0.00 15.00 0.00 25.00 0.00 15.00 40.44%
NAPS 7.203 6.978 7.0082 7.0359 6.7607 6.6581 6.5117 6.93%
Adjusted Per Share Value based on latest NOSH - 4,247,373
31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 CAGR
RPS 100.91 96.70 92.85 89.87 90.61 79.94 68.49 29.38%
EPS 13.44 14.91 18.55 17.47 17.71 16.07 14.56 -5.18%
DPS 24.58 0.00 14.68 0.00 24.28 0.00 14.29 43.41%
NAPS 7.0822 6.8609 6.8603 6.855 6.5648 6.433 6.2052 9.18%
Price Multiplier on Financial Quarter End Date
31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 CAGR
Date 29/12/23 29/09/23 30/06/23 31/03/23 30/12/22 30/09/22 30/06/22 -
Price 5.45 5.43 5.43 5.58 5.79 5.56 5.73 -
P/RPS 5.31 5.52 5.72 6.05 6.20 6.72 7.97 -23.66%
P/EPS 39.87 35.81 28.65 31.12 31.74 33.43 37.50 4.15%
EY 2.51 2.79 3.49 3.21 3.15 2.99 2.67 -4.02%
DY 4.59 0.00 2.76 0.00 4.32 0.00 2.62 45.17%
P/NAPS 0.76 0.78 0.77 0.79 0.86 0.84 0.88 -9.28%
Price Multiplier on Announcement Date
31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 CAGR
Date 27/02/24 27/11/23 29/08/23 26/05/23 27/02/23 29/11/22 29/08/22 -
Price 5.68 5.57 5.70 5.45 5.60 5.67 5.81 -
P/RPS 5.53 5.66 6.01 5.91 6.00 6.85 8.08 -22.28%
P/EPS 41.55 36.73 30.08 30.39 30.70 34.09 38.02 6.08%
EY 2.41 2.72 3.32 3.29 3.26 2.93 2.63 -5.64%
DY 4.40 0.00 2.63 0.00 4.46 0.00 2.58 42.60%
P/NAPS 0.79 0.80 0.81 0.77 0.83 0.85 0.89 -7.61%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment